Eslicarbazepine acetate (ESL) is a novel, once-daily antiseizure medication. We evaluated
the efficacy and safety profile of ESL treatment in epilepsy patients at a single tertiary …

Objective: We evaluated the efficacy and side effect profile of ESL treatment in epilepsy
patients at our center. Background: Eslicarbazepine acetate (ESL) is a novel, once-daily anti …

Objective The objective of this study was to evaluate long-term safety and tolerability
outcomes in two open-label extension (OLE) studies of adjunctive eslicarbazepine acetate …

Objective: To evaluate the safety and tolerability of adjunctive eslicarbazepine acetate (ESL)
in pediatric patients (aged 4-17 years) with refractory focal seizures. Methods: Pooled safety …

Purpose This was a phase-III, randomized, double-blind, placebo-controlled study aimed to
evaluate efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy in …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …

Background Eslicarbazepine acetate (ESL) is a third-generation anti-seizure drug used in
patients with focal-onset seizures. This retrospective study aimed to evaluate the efficacy …

Eslicarbazepine acetate (Zebinix®), a voltage-gated sodium channel blocker, is a once-
daily, orally administered anti-seizure medication available in the EU for use as …

Eslicarbazepine acetate (ESL) is a once daily new third generation antiepileptic drug that
shares the basic chemical structure of carbamazepine and oxcarbazepine–a dibenzazepine …

Purpose Eslicarbazepine acetate (ESL) is a new generation voltage-gated sodium channel
blocker. It has completed one phase II clinical trial and three phase III clinical trials, two of …